9780309120883 - breakthrough business models: drug development for rare and neglected diseases and individualized therapies: drug development for rare and neglected ... individualized therapies: workshop summary di wizemann, theresa m.; robinson, sally; giffin, robert; institute of medicine (u. s.) (11 risultati)
Breakthrough Business Models : Drug Development for Rare and Neglected Diseases and Individualized Therapies
Wizemann, Theresa M.; Robinson, Sally; Giffin, Robert; Institute of Medicine (U. S.) (COR)
- Brossura
Da: GreatBookPrices, Columbia, MD, U.S.A.GreatBookPrices
Contatta il venditoreVenditore con 5 stelleCondizione: Usato - Come nuovo
EUR 54,87
EUR 2,30 spedizioneSpedito in U.S.A.Quantità: 1 disponibili
Condizione: As New. Unread book in perfect condition.
Breakthrough Business Models : Drug Development for Rare and Neglected Diseases and Individualized Therapies
Wizemann, Theresa M.; Robinson, Sally; Giffin, Robert; Institute of Medicine (U. S.) (COR)
- Brossura
Da: GreatBookPrices, Columbia, MD, U.S.A.GreatBookPrices
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 59,45
EUR 2,30 spedizioneSpedito in U.S.A.Quantità: 1 disponibili
Condizione: New.
- Brossura
Da: Grand Eagle Retail, Bensenville, IL, U.S.A.Grand Eagle Retail
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 61,83
Spedizione gratuitaSpedito in U.S.A.Quantità: 1 disponibili
Paperback. Condizione: new. Paperback. The process for developing new drug and biologic products is extraordinarily expensive and time-consuming. Although large pharmaceutical companies may be able to afford the cost of development because they can expect a large return on investment, organizations developing drugs to treat rare… and neglected diseases are unable to rely on such returns. On June 23, 2008, the Institute of Medicine's Forum on Drug Discovery, Development, and Translation held a public workshop, "Breakthrough Business Models: Drug Development for Rare and Neglected Diseases and Individualized Therapies," which sought to explore new and innovative strategies for developing drugs for rare and neglected diseases. The process for developing new drug and biologic products is extraordinarily expensive and time-consuming. Although large pharmaceutical companies may be able to afford the cost of development because they can expect a large return on investment, organizations developing drugs to treat rare and neglected diseases are unable to rely on such returns. On June 23, 2008, the Institute of Medicine's Forum on Drug Discovery, Development, and Translation held a public workshop, "Breakthrough Business Models: Drug Development for Rare and Neglected Diseases and Individualized Therapies," which sought to explore new and innovative strategies for developing drugs for rare and neglected diseases. Shipping may be from multiple locations in the US or from the UK, depending on stock availability.
Breakthrough Business Models: Drug Development for Rare and Neglected Diseases and Individualized Therapies: Workshop Summary
Wizeman, Theresa; Robinson, Sally; Giffin, Robert; Forum on Drug Discovery, Development, and Translation; Board on Health Sciences Policy; Institute
- Brossura
Da: Kennys Bookshop and Art Galleries Ltd., Galway, GY, IrlandaKennys Bookshop and Art Galleries Ltd.
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 62,87
EUR 10,50 spedizioneSpedito da Irlanda a U.S.A.Quantità: 10 disponibili
Condizione: New. Num Pages: 150 pages. Category: (P) Professional & Vocational. Dimension: 229 x 152 x 10. Weight in Grams: 249. . 2009. New. paperback. . . . .
Breakthrough Business Models : Drug Development for Rare and Neglected Diseases and Individualized Therapies
Wizemann, Theresa M.; Robinson, Sally; Giffin, Robert; Institute of Medicine (U. S.) (COR)
- Brossura
Da: GreatBookPricesUK, Woodford Green, Regno UnitoGreatBookPricesUK
Contatta il venditoreVenditore con 5 stelleCondizione: Usato - Come nuovo
EUR 59,67
EUR 17,28 spedizioneSpedito da Regno Unito a U.S.A.Quantità: 1 disponibili
Condizione: As New. Unread book in perfect condition.
Breakthrough Business Models: Drug Development for Rare and Neglected Diseases and Individualized Therapies
Wizemann, Theresa M./ Robinson, Sally/ Giffin, Robert/ Institute of Medicine (U. S.)
- Brossura
Da: Revaluation Books, Exeter, , Regno UnitoRevaluation Books
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 69,39
EUR 11,52 spedizioneSpedito da Regno Unito a U.S.A.Quantità: 1 disponibili
Paperback. Condizione: Brand New. 150 pages. 8.80x6.00x0.40 inches. In Stock.
Breakthrough Business Models : Drug Development for Rare and Neglected Diseases and Individualized Therapies
Wizemann, Theresa M.; Robinson, Sally; Giffin, Robert; Institute of Medicine (U. S.) (COR)
- Brossura
Da: GreatBookPricesUK, Woodford Green, Regno UnitoGreatBookPricesUK
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 69,78
EUR 17,28 spedizioneSpedito da Regno Unito a U.S.A.Quantità: 1 disponibili
Condizione: New.
Breakthrough Business Models: Drug Development for Rare and Neglected Diseases and Individualized Therapies: Workshop Summary
Wizeman, Theresa; Robinson, Sally; Giffin, Robert; Forum on Drug Discovery, Development, and Translation; Board on Health Sciences Policy; Institute
- Brossura
Da: Kennys Bookstore, Olney, MD, U.S.A.Kennys Bookstore
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 79,56
EUR 9,16 spedizioneSpedito in U.S.A.Quantità: 10 disponibili
Condizione: New. Num Pages: 150 pages. Category: (P) Professional & Vocational. Dimension: 229 x 152 x 10. Weight in Grams: 249. . 2009. New. paperback. . . . . Books ship from the US and Ireland.
- Brossura
Da: THE SAINT BOOKSTORE, Southport, , Regno UnitoTHE SAINT BOOKSTORE
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 75,79
EUR 15,60 spedizioneSpedito da Regno Unito a U.S.A.Quantità: 1 disponibili
Paperback / softback. Condizione: New. New copy - Usually dispatched within 4 working days.
Breakthrough Business Models: Drug Development for Rare and Neglected Diseases and Individualized Therapies: Workshop Summary
Institute of Medicine|Board on Health Sciences Policy|Forum on Drug Discovery Development and
- Brossura
Da: moluna, Greven, , Germaniamoluna
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 53,75
EUR 48,99 spedizioneSpedito da Germania a U.S.A.Quantità: 1 disponibili
Condizione: New.
- Brossura
Da: AussieBookSeller, Truganina, VIC, AustraliaAussieBookSeller
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 96,30
EUR 32,28 spedizioneSpedito da Australia a U.S.A.Quantità: 1 disponibili
Paperback. Condizione: new. Paperback. The process for developing new drug and biologic products is extraordinarily expensive and time-consuming. Although large pharmaceutical companies may be able to afford the cost of development because they can expect a large return on investment, organizations developing drugs to treat rare… and neglected diseases are unable to rely on such returns. On June 23, 2008, the Institute of Medicine's Forum on Drug Discovery, Development, and Translation held a public workshop, "Breakthrough Business Models: Drug Development for Rare and Neglected Diseases and Individualized Therapies," which sought to explore new and innovative strategies for developing drugs for rare and neglected diseases. The process for developing new drug and biologic products is extraordinarily expensive and time-consuming. Although large pharmaceutical companies may be able to afford the cost of development because they can expect a large return on investment, organizations developing drugs to treat rare and neglected diseases are unable to rely on such returns. On June 23, 2008, the Institute of Medicine's Forum on Drug Discovery, Development, and Translation held a public workshop, "Breakthrough Business Models: Drug Development for Rare and Neglected Diseases and Individualized Therapies," which sought to explore new and innovative strategies for developing drugs for rare and neglected diseases. Shipping may be from our Sydney, NSW warehouse or from our UK or US warehouse, depending on stock availability.
